ElendiLabs — Regulatory consultancy platform connecting medical device and pharmaceutical manufacturers with verified experts worldwide
All regulatory hubs
Regulatory hub

Overview of the Medicines and Healthcare products Regulatory Agency (MHRA) and Medical Device Regulation in the UK

An overview of the MHRA's role in regulating medical devices in the UK, including the UKCA marking, manufacturer registration, and post-market surveillance.

Overview

Summary of this regulator or jurisdiction and how it relates to market access.

Official regulator site

Introduction

The Medicines and Healthcare products Regulatory Agency (MHRA) is the executive agency of the Department of Health and Social Care responsible for regulating the UK medical devices market.

Role and Responsibilities

The MHRA's core functions include:

  • Market Surveillance: Monitoring the safety and performance of medical devices on the UK market.
  • Enforcement: Taking decisions over the marketing and supply of devices in the UK.
  • Designation of Bodies: Appointing and monitoring UK conformity assessment bodies (Approved Bodies).
  • Vigilance: Managing the reporting of adverse incidents and field safety corrective actions.

Key Regulatory Requirements

  • Registration: All medical devices, including IVDs and custom-made devices, must be registered with the MHRA before being placed on the Great Britain market.
  • UKCA Marking: The UKCA (UK Conformity Assessed) marking is the mandatory product marking for devices in Great Britain (transitional recognition of CE marks is currently in place).
  • UK Responsible Person (UKRP): Manufacturers based outside the UK must appoint a UKRP to act on their behalf and manage registrations.
  • Northern Ireland: Under the Northern Ireland Protocol, EU rules (MDR and IVDR) apply, and devices require CE marking.

Post-Market Surveillance

Manufacturers must ensure continuous compliance and report incidents to the MHRA. Recent legislation has strengthened these requirements to facilitate better risk management.

Articles & guides

Insight articles mapped to this region on ElendiLabs.

Registration

May 4, 2026

Mastering Global MedTech Access: A Technical Roadmap Across Six Strategic Jurisdictions in 2026

An in-depth technical analysis of the 2026 global regulatory landscape, examining the transition from the gatekeeper model to Continuous Lifecycle Compliance across the EU, UK, Mexico, India, Indonesia, and Malaysia.

Read article

Registration

March 25, 2026

Navigating the UK Medical Device Regulatory Landscape in 2026

Jack Bacon, Founder of MedTech Integrity, provides practitioner insights into the flexible, internationally aligned UK regulatory system of 2026, covering UKCA, Reliance Routes, and liability shifts.

Read article

Post Market Surveillance

March 6, 2026

Device-Specific Vigilance Guidance for Joint Replacement Implants

MHRA guidance on reporting adverse incidents for joint replacement implants, detailing reportable scenarios like mechanical failure, aseptic loosening within expected life, anomalous soft tissue changes, and systemic effects from high blood metal ions to ensure compliance with UK regulations.

Read article

Other

March 6, 2026

Written Confirmations for Exporting Active Substances from Great Britain to EEA and Northern Ireland

MHRA guidance on written confirmations required for exporting active substances manufactured in Great Britain to the EEA and Northern Ireland, detailing purpose, third country status, generation process, validity, and requirements for distributors and biological products.

Read article

Other

March 6, 2026

MHRA Guidance on Resuming UK On-Site GxP Inspections

MHRA guidance on resuming on-site GxP inspections in the UK post-COVID-19 suspension, emphasizing a risk-based approach with remote and on-site methods, prioritizing public health risks, and adhering to government safety guidelines.

Read article

Other

March 6, 2026

UK Decentralised Manufacture Designation Step Guidance

MHRA's mechanism for evaluating justifications for decentralised manufacture (DM) of medicinal products, including criteria for point of care and modular manufacture, application process, and timelines to provide regulatory clarity for innovators.

Read article

Other

March 6, 2026

UK Guidance on Decentralised Manufacture for Clinical Trials CTA and GCP

Guidance on decentralised manufacture (DM) for investigational medicinal products in clinical trials, covering CTA applications, GCP considerations, control sites, IMPD requirements, real-time release testing, and blinding in trials to ensure compliance and safety.

Read article

Other

March 6, 2026

UK Medical Technology Innovation Classification Framework

The UK Medical Technology Innovation Classification Framework provides a common language for describing innovations in medical technologies, classifying them as incremental, transformative, or disruptive to streamline adoption pathways and support the health and social care system.

Read article

Other

March 5, 2026

Supplementary Guidance on UK-Wide Licensing for Human Medicines

MHRA supplementary guidance on implementing UK-wide licensing for human medicines post-Windsor Framework, including transitional arrangements, product categorisation, product information divergence, reference medicinal products, comparator products, and well-established use to ensure unified authorisation across Great Britain and Northern Ireland.

Read article

Other

March 5, 2026

Guidance on Risk Minimisation Measures for Medicines in the UK

MHRA guidance for healthcare professionals on risk minimisation measures for medicines, detailing purpose, decisions, and examples including patient guidance, healthcare professional materials, patient cards, educational tools, controlled access, controlled distribution, and pregnancy prevention programmes to facilitate safe and effective use.

Read article

Other

March 5, 2026

Pathway for Introducing New Medicines in the UK NHS

Overview of the UK pathway for introducing new medicines into the NHS, including pre-submission processes, marketing authorisation routes, health technology evaluations, and mechanisms for early access and advice to accelerate patient access to innovative treatments.

Read article

Other

March 5, 2026

UK Interpretation of Labelling Requirements for E-Liquids in Great Britain

UK government guidance on interpreting labelling requirements for e-liquids under the Tobacco and Related Products Regulations 2016 in Great Britain, covering definitions, unit packets, outer packaging, and multipacks to ensure consumer safety and information access.

Read article

Other

March 5, 2026

UK Safety Communications for Medicines, Medical Devices, and Healthcare Products

This guidance details MHRA's safety communications for medicines, medical devices, and healthcare products, including types like National Patient Safety Alerts, Drug Safety Updates, Medical Device Safety Bulletins, recalls, and manufacturer communications, emphasizing patient safety and risk minimization.

Read article

Other

March 5, 2026

Guiding Principles for Good Machine Learning Practice in Medical Device Development

Joint guiding principles from FDA, Health Canada, and MHRA for Good Machine Learning Practice (GMLP) in developing safe, effective, and high-quality AI/ML-enabled medical devices, addressing unique considerations and promoting collaboration.

Read article

Other

March 5, 2026

Guidance on Electronic Instructions for Use of Medical Devices in the UK

This guidance outlines the UK regulations allowing manufacturers to provide electronic instructions for use (eIFU) for certain medical devices, including definitions, applicable device types, conditions, risk assessments, labelling requirements, and website provisions to maintain safety and improve usability.

Read article

Other

March 5, 2026

UK Parallel Import Licences Under the Windsor Framework Agreement

Guidance on UK Parallel Import Licences (PLPIs) following the Windsor Framework, including transitions from Parallel Distribution Notices (PDNs), labelling requirements, FMD disapplication, and supply of existing stock from 1 January 2025.

Read article

Other

March 5, 2026

Guiding Principles for Predetermined Change Control Plans in ML-Enabled Medical Devices

Joint guiding principles from FDA, Health Canada, and MHRA on Predetermined Change Control Plans (PCCPs) for machine learning-enabled medical devices (MLMDs) to manage modifications, ensure safety, effectiveness, and support innovation throughout the product lifecycle.

Read article

Other

March 5, 2026

Submitting Changes to Labelling and Patient Information Leaflets for Medicines

This guidance explains how to submit changes to labelling and patient information leaflets (PILs) for medicines in the UK, covering self-certification notifications for most changes and full assessments for specific cases, including processes, requirements, and timelines.

Read article

Other

March 5, 2026

Oversight and Monitoring of Investigational Medical Product Trials in the UK

This guidance outlines oversight and monitoring activities for investigational medical product trials, emphasizing risk-based approaches, documentation, adaptation strategies, and responsibilities to ensure compliance, participant safety, and reliable results.

Read article

Other

March 5, 2026

Supplying Authorised Medicines to Northern Ireland Under the Windsor Framework

This guidance details the regulations for supplying authorised medicines to Northern Ireland from 1 January 2025, including UK-wide marketing authorisations, supply from Great Britain, and identification of compliant medicines under the Windsor Framework.

Read article

Other

March 5, 2026

Obtaining Scientific Advice from MHRA for Medicines Development

The MHRA provides scientific advice on medicines at any development stage, offering written advice or meetings, including joint sessions with NICE, to guide regulatory and development strategies.

Read article

Other

March 4, 2026

Legal Requirements for Children's Medicines in the UK

This guidance provides an overview of the legal requirements for children's medicines in the UK, including paediatric investigation plans, studies, formulations, excipients, clinical trials, labelling, packaging, patient information, and pharmacovigilance to ensure safety and efficacy for paediatric populations.

Read article

Other

March 4, 2026

MHRA Guidance on Supplying Unlicensed Medicinal Products (Specials) in the UK

This MHRA guidance outlines the regulations for manufacturing, importing, distributing, and supplying unlicensed medicinal products ('specials') for human use in the UK, including conditions for exemptions, responsibilities, and compliance requirements to meet special patient needs.

Read article

Other

March 4, 2026

Reclassifying Medicines in the UK: From Prescription to Over-the-Counter

This guide details the process for reclassifying medicines in the UK from prescription-only (POM) to pharmacy (P) or general sale list (GSL) status, including requirements, evidence, procedures, and public consultations to ensure safe public access.

Read article

Registration

March 4, 2026

Guide to Manufacturer and Wholesaler Licences for Medicines in the UK

This guide explains how to apply for, update, and cancel licences for manufacturing, importing, and wholesaling human and veterinary medicines in the UK, including compliance with GMP and GDP, application processes, fees, and inspections.

Read article

Clinical Trials

March 4, 2026

Applying for Clinical Trial Approval for Medicines in the UK

The Medicines and Healthcare products Regulatory Agency (MHRA) outlines the process for applying for clinical trial authorisation in the UK, including combined review via IRAS, requirements for sponsors, IVD devices, documents like IMPD and IB, assessment timelines, fees, and registration obligations.

Read article

Clinical Trials

March 4, 2026

Modifying Clinical Trial Approvals for Medicines in the UK

MHRA provides guidance on modifying clinical trial approvals for medicines, categorizing modifications as substantial (Route A or B), important detail, or minor, with processes for submission via IRAS, validation, review timelines, fees, and examples.

Read article

Clinical Trials

March 4, 2026

UK Clinical Trials Regulations Transitional Arrangements

The MHRA outlines transitional arrangements for clinical trials under the amended Medicines for Human Use (Clinical Trials) Regulations, effective 28 April 2026, distinguishing 'old rules' and 'new rules' trials, with specific provisions for approvals, transparency, GCP, pharmacovigilance, IMP manufacturing, labelling, and enforcement.

Read article

Other

March 3, 2026

Applying for a UK Marketing Authorisation for Medicines

The MHRA provides guidance on applying for marketing authorisations for medicines in the UK, covering submission processes, required formats like eCTD, fees, assessment timelines, and specific requirements for generics, biosimilars, herbal, homeopathic medicines, and established medicines.

Read article

Clinical Trials

March 3, 2026

Applying for Clinical Trial Authorisation for Medicines in the UK

The Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA) oversee clinical trial authorisations in the UK through a combined review process, requiring submission via IRAS for investigational medicinal products, with specific requirements for IVDs, fees, timelines, and post-authorisation management.

Read article

Clinical Trials

March 3, 2026

UK Guidance on Labelling for Clinical Trial Medicines

MHRA provides guidance on labelling investigational medicinal products (IMPs) for clinical trials, including requirements for unauthorised and authorised products, exemptions, blinding considerations, and decentralised manufacturing, in line with the Medicines for Human Use (Clinical Trials) Regulations.

Read article

Other

March 3, 2026

Applying for a UK Marketing Authorisation for Medicines

The Medicines and Healthcare products Regulatory Agency (MHRA) requires companies to obtain a Marketing Authorisation (MA) before selling prescription or over-the-counter medicines in the UK, following national, decentralised, mutual recognition, or centralised procedures, with specific pathways for generics, biosimilars, and novel drugs.

Read article

Other

January 19, 2026

UK Regulatory Guidance on Traditional Herbal and Homeopathic Medicinal Products

This guidance explains how the Medicines and Healthcare products Regulatory Agency (MHRA) handles registrations for **traditional herbal medicinal products** and **homeopathic medicinal products** under UK law, particularly in the context of post-Brexit regulatory changes.

Read article

Other

January 18, 2026

UK Guidance on Active Substance Master Files and Certificates of Suitability

This guidance explains how the UK Medicines and Healthcare products Regulatory Agency (MHRA) handles **Active Substance Master Files (ASMFs)** and **Certificates of Suitability (CEPs)** within national Marketing Authorisation Applications (MAAs) and variations.

Read article

Other

January 18, 2026

UK Reference Medicinal Products: Requirements and Use for Marketing Authorisations

Reference Medicinal Products (RMPs) are essential in the UK for supporting abridged marketing authorisation applications such as generics, biosimilars or hybrid medicines, and this guidance explains what constitutes a valid RMP and how it applies in the post-Windsor Framework regulatory environment.

Read article

Import & Export

January 15, 2026

UK Controls on Parallel Export and Hoarding of Restricted Medicines

The UK government restricts the **export and hoarding** of certain medicines already placed on the UK market where there is evidence of **critical shortages** or risk of shortages, to protect supply for UK patients.

Read article

Post Market Surveillance

January 15, 2026

Implementation of the Future Regulation of Medical Devices in the UK

The MHRA has outlined a phased implementation timeline for the future UK medical device regulations, ensuring a smooth transition for manufacturers while maintaining patient safety and market supply.

Read article

Registration

January 15, 2026

Registering Medical Devices for the UK Market (MHRA Guidance)

Comprehensive guide on MHRA registration requirements for medical devices in Great Britain and Northern Ireland, including the role of the UK Responsible Person and fee structures.

Read article

Post Market Surveillance

January 12, 2026

UK Pharmacovigilance: Sending and Receiving Information on Adverse Drug Reactions

The MHRA’s guidance outlines how marketing authorisation holders and others should send and receive reports about adverse drug reactions (ADRs) to support medicine safety and signal detection.

Read article

Other

January 11, 2026

Medicines Marketing Authorisation: Ownership Transfer in the UK

This article explains how to change the ownership of a UK medicines marketing authorisation (MA), including application requirements, documentation, and procedural steps under MHRA guidance.

Read article

Other

January 11, 2026

Guidance on Field Safety Notices for Medical Device Manufacturers in the UK

Field Safety Notices (FSNs) are critical communications from device makers about safety issues and corrective actions; the MHRA provides guidance to help manufacturers prepare and distribute effective FSNs.

Read article

Other

January 10, 2026

Guidance for Wholesalers and Manufacturers under the Windsor Framework in the UK

The Windsor Framework agreement provides specific arrangements for the supply of human medicines to Northern Ireland, offering wholesalers and manufacturers pathways to place products on the market in NI using UK-wide or UK-only authorisations while maintaining access to the full UK market, with key changes to labelling, packaging, and regulatory requirements effective from 1 January 2025.

Read article

Registration

January 10, 2026

Regulation and Licensing of Advanced Therapy Medicinal Products in the UK

Advanced therapy medicinal products (ATMPs) in the UK are regulated by the MHRA, which sets out classification, clinical trial requirements, marketing authorisations, and manufacturing and hospital-exemption pathways.

Read article

Import & Export

January 7, 2026

Guide to Applying for a Parallel Import Licence for Medicines in the UK

A parallel import licence allows medicines authorised in another EEA Member State to be marketed in the UK where they have no therapeutic difference from the UK product. Applicants must meet specific criteria and submit detailed documentation to the MHRA.

Read article

Post Market Surveillance

January 4, 2026

UK Pharmacovigilance: QPPV and PSMF Obligations for Marketing Authorisation Holders

In the UK, all marketing authorisation holders must appoint a Qualified Person for Pharmacovigilance (QPPV) residing in the UK or EU/EEA to oversee the pharmacovigilance system, and maintain a Pharmacovigilance System Master File (PSMF) accessible electronically from the UK, with specific notification and update procedures via the MHRA portal.

Read article

Other

January 4, 2026

How to Obtain Regulatory Advice from the MHRA for Medical Devices

The MHRA provides a regulatory advice service for medical devices and in vitro diagnostic devices to help navigate UK regulatory requirements where guidance application is unclear.

Read article

Other

January 3, 2026

Key UK Guidance for Specials Manufacturers

The UK guidance clarifies good manufacturing practice (GMP) requirements for manufacturers producing unlicensed medicinal products (‘specials’) under a Specials Manufacturing (MS) licence.

Read article

Other

January 2, 2026

UK-Wide Labelling and Packaging Requirements After Windsor Framework

Following the Windsor Framework agreement, new labelling and packaging requirements ensure that all medicinal products for human use supplied in the UK carry consistent UK-specific packaging and labelling, including the ‘UK Only’ designation.

Read article

Other

December 21, 2025

Navigating the UK Early Access to Medicines Scheme for Applicants

Guidance on applying for the UK Early Access to Medicines Scheme (EAMS), which enables patients with life-threatening or debilitating conditions to access promising medicines before full marketing authorisation.

Read article

Other

December 19, 2025

MHRA Guidance on Licensing Biosimilar Medicinal Products in the UK

The MHRA guidance outlines a tailored, case-by-case approach for licensing biosimilars in Great Britain, requiring robust comparative quality, non-clinical and clinical data to demonstrate similarity to the reference product while allowing reduction in certain studies based on scientific justification, with emphasis on extrapolation, interchangeability and post-authorisation monitoring.

Read article

Other

December 18, 2025

Streamlined Rolling Review Route for UK Marketing Authorisation

The rolling review allows applicants to submit modules of their eCTD dossier to the MHRA for pre-assessment incrementally rather than submitting a full consolidated dossier at once.

Read article

Post Market Surveillance

December 15, 2025

Medical Devices: Post-Market Surveillance (PMS) Requirements in the UK

This article explains the UK's post-market surveillance (PMS) framework for medical devices, covering manufacturer obligations, PMS plans, and reporting requirements under the MHRA.

Read article

Other

December 14, 2025

MHRA Roadmap for Reforming Regulation of Software and AI as Medical Devices in the UK

The MHRA's Software and AI as a Medical Device Change Programme roadmap outlines reforms to ensure clear, proportionate regulation that protects patients while fostering responsible innovation in SaMD and AIaMD, structured around work packages for qualification, classification, premarket/post-market requirements, cybersecurity, and AI-specific challenges.

Read article

Other

December 11, 2025

Unified UK-Wide Licensing of Human Medicines

From 1 January 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) will issue licences that cover the **whole United Kingdom** for human medicines, replacing separate Great Britain (GB) and Northern Ireland (NI) authorisations.

Read article

Other

December 5, 2025

Conditional Marketing Authorisations, Exceptional Circumstances Authorisations, and National Scientific Advice in the UK

The MHRA offers conditional marketing authorisations for medicines addressing unmet needs with less comprehensive data, exceptional circumstances authorisations for situations where full data cannot be obtained, and national scientific advice to support development and regulatory decisions, all aimed at facilitating timely patient access while ensuring appropriate post-authorisation obligations.

Read article

Clinical Trials

November 26, 2025

Clinical Trials for Medicines: Ending a Clinical Trial in the UK

Guidance on legal and regulatory **steps to formally end a clinical trial** in the UK, including notifying authorities, publishing results, and dealing with approval lapses.

Read article

Medical Advertisements

November 16, 2025

Legal Pathways for Marketing Authorisation Applications in the United Kingdom

The UK regulatory framework defines several legal bases for marketing authorisation applications, allowing applicants to rely on full, abridged, hybrid, bibliographic, or well-established use pathways depending on the nature of the medicinal product and available data.

Read article

Import & Export

November 16, 2025

UK Export Controls for Medicines: Special Regulatory Rules and Compliance Duties

When exporting drugs and medicines from the UK, businesses must comply with special regulatory rules that govern licensing status, documentation, controlled substances, and destination-specific requirements, even when products are not intended for the UK market.

Read article

Other

October 1, 2025

Variations to Marketing Authorisations (MAs) in the UK

Guidance on how to submit and classify applications to change the terms or conditions of existing marketing authorisations for medicinal products in the UK.

Read article

Other

September 22, 2025

Defining a Clear Intended Purpose for Software as a Medical Device (SaMD) in the UK

A well-crafted intended purpose is essential for SaMD compliance in the UK, as inadequate definition seriously impairs quality management, clinical evidence generation, risk management, and post-market surveillance, potentially failing key regulatory requirements.

Read article